LipoCure Overview
LipoCure is developing a number of therapeutics utilizing proprietary liposome-based nano drugs with novel drug-loading capabilities and drug-release mechanisms. LipoCure's proprietary platform implements an approach that allows for remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. This technology is designed to produce an enhanced permeability and retention effect, a significantly improved therapeutic effect, and reduced side effects. It can be used in conjunction with several well-established drugs used for the treatment of rheumatoid arthritis, multiple sclerosis, and cancer. LipoCure's founder is professor Yechezkel Barenholz, the co-developer of Doxil.
Cumulative Funding Raised Over Time ($)
Latest News
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8M |
| Last funding | $8M |
| Stage | A |
| Rounds | 1 |
| Investors | 2 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | lipocurerx.com/ |
Locations
Hadassah Ein Kerem Campus, Jerusalem, Israel
Photos & Videos
1 item(s)
